Objective: Exploring the clinical value of magnetic resonance imaging (MRI) combined with serum SCL/TALI breakpoint (STIL) and clusterin in the assessment of efficacy after primary liver cancer intervention. Methods: Eighty patients with primary liver cancer who underwent hepatic artery chemoembolization from June 2020 to June 2023 were selected, and digital silhouette angiography was used as the “ gold standard” for evaluating the efficacy of the patients after intervention, and they were divided into the recurrence group (57 cases) and the non-recurrence group (23 cases). We compared the levels of serum STIL and Clusterin between the two groups, used ROC curve to analyze the value of serum STIL and Clusterin in the assessment of post-interventional efficacy of primary liver cancer, analyzed the results of MRI, and analyzed the assessment of postoperative efficacy of patients by MRI combined with serum STIL and Clusterin using the four-compartmental table method. Results: Serum STIL and Clusterin levels were higher in the recurrence group than in the non-recurrence group (P<0.05). The AUCs of serum STIL and Clusterin for the assessment of the efficacy of primary hepatocellular carcinoma after intervention were 0.738 and 0.744, respectively, and the optimal cutoff values were 36.32 ng/mL and 85.25 μg/mL, respectively. The results of the MRI examination showed that primary hepatocellular carcinoma recurrence after intervention in 45 cases and no recurrence in 35 cases; the sensitivity o25f MRI in assessing the efficacy of primary liver cancer after intervention was 70.18%, the specificity was 78.26%, and the accuracy was 72.50%. The accuracy of MRI combined with serum STIL and Clusterin in assessing the efficacy of primary liver cancer after intervention was 90.00%, the sensitivity was 94.74%, the specificity was 78.26%, and the accuracy and sensitivity of the three combined for the assessment of post-interventional efficacy of primary hepatocellular carcinoma were significantly higher than those of each index alone (P<0.05). Conclusion: Serum STIL and Clusterin levels were significantly up-regulated in patients with recurrence after primary hepatocellular carcinoma intervention, and MRI combined with serum STIL and Clusterin is of high value in assessing the efficacy of primary hepatocellular carcinoma after intervention.
Key words
magnetic resonance imaging /
SCL/TALI breakpoint /
clusterin /
primary liver cancer /
catheter hepatic artery chemoembolization
{{custom_keyword}} /
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] 马俊, 于倩, 王亚华, 等. 针刺至阳八阵穴联合巴氯芬治疗原发性肝癌介入术后顽固性呃逆患者的临床观察[J]. 中西医结合肝病杂志, 2022, 32(1):20-22,27.
[2] He Z, Huang Q, Liao Y, et al. Artificial intelligence algorithm in classification and recognition of primary hepatic carcinoma images under magnetic resonance imaging[J]. Contrast Media Mol Imaging, 2022:8950600.
[3] Ji SF, Wen SL, Sun Y, et al. The biological function and clinical significance of STIL in osteosarcoma[J]. Cancer Cell Int, 2021, 21(1):218-36.
[4] Narahara S, Watanabe T, Nagaoka K, et al. Clusterin and related scoring index as potential early predictors of response to sorafenib in hepatocellular carcinoma[J]. Hepatol Commun, 2022, 6(5):1198-1212.
[5] Chen Z, Fan Z, Dou X, et al. Inactivation of tumor suppressor gene Clusterin leads to hyperactivation of TAK1-NF-κB signaling axis in lung cancer cells and denotes a therapeutic opportunity[J]. Theranostics, 2020, 10(25):11520-11534.
[6] 常祖宽, 王晓伟, 马文芳, 等. MRI在原发性肝癌早期诊断及TACE介入治疗术后疗效评价中的应用[J]. 中国CT和MRI杂志, 2022, 20(7):101-103.
[7] 刘思宏, 谢琉嘉, 周志明, 等. CEUS联合MRI增强扫描早期评价射频消融治疗原发性肝癌患者疗效研究[J]. 实用肝脏病杂志, 2023, 26 (6):895-898.
[8] Ma K, Liu J, Wang Y, et al. Relationship between plasma cell-free DNA (cfDNA) and prognosis of TACE for primary hepatocellular carcinoma[J]. J Gastrointest Oncol, 2020, 11(6):1350-1363.
[9] 朱苏滨. CT与MRI应用于原发性肝癌介入术后疗效评估的临床价值研究[J]. 影像研究与医学应用, 2023, 7(13):117-119.
[10] Li J, Yang Z, Qi Y, et al. STIL acts as an oncogenetic driver in a primary cilia-dependent manner in human cancer[J]. Front Cell Dev Biol, 2022, 10(1):804419-804433.
[11] Song H, Zhao H, Chen C, et al. Elevated STIL predicts poor prognosis in patients with hepatocellular carcinoma[J]. Medicine (Baltimore), 2023, 102(7):e33004-e33012.
[12] Xu L, Zhang S, Feng J, et al. ncRNAs-mediated overexpression of STIL predict unfavorable prognosis and correlated with the efficacy of immunotherapy of hepatocellular carcinoma[J]. Cancer Cell Int, 2023, 23(1):44-66.
[13] Téllez T, Martin-García D, Redondo M, et al. Clusterin expression in colorectal carcinomas[J]. Int J Mol Sci, 2023, 24(19):14641-14658.
[14] Wang X, Liu Y, Qin Q, et al. Clusterin role in hepatocellular carcinoma patients treated with oxaliplatin[J]. Biosci Rep, 2020, 40(2):BSR20200071.
[15] 黄蓉, 樊斌, 丁俊. 可切除肝细胞癌患者癌旁肝组织中分泌型簇集蛋白的表达与术后生存预后的相关性[J]. 实用临床医药杂志, 2022, 26(8):37-43.
[16] 欧阳婷雪, 杨静, 桑倩. MRI与CT对肝癌TACE术后疗效及残灶活性的评价[J]. 中国CT和MRI杂志, 2023, 21(11):94-96.
[17] 时文伟. 肝癌临床诊断中应用肝脏增强CT与肝脏MRI技术的诊断效果观察[J]. 影像研究与医学应用, 2023, 7(17):169-171.
[18] 郑佳, 黄云华, 张显明, 等. MSCT联合MRI成像技术在原发性肝癌患者介入术前诊断及术后疗效评估中的应用[J]. 中国CT和MRI杂志, 2021, 19(10):104-106,109.
[19] 刘晓侃, 洪鑫, 许若男, 等. CT影像组学联合血清炎症参数预测肝癌根治术后辅助TACE的早期复发[J]. 介入放射学杂志, 2023, 32(11):1075-1082.
{{custom_fnGroup.title_en}}
Footnotes
{{custom_fn.content}}
PDF(3053 KB)
